Evotec Appoints Rui Wang as EVP, Head of Global In Silico and AI 

Evotec SE has appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. 

In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science align for Evotec’s commercial value proposition.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said, “Rui will play a key role in our ongoing effort to make Evotec’s drug discovery and development enterprise a powerful engine of innovation, integration and operational efficiency. Advanced computational tools are essential to enhancing the value of both our business segments – Drug Discovery and Preclinical Development as well as Just – Evotec Biologics. These tools are not a separate entity but are embedded in everything we do to discover and develop new therapies.”

Mr. Wang most recently served as Head of Data, Analytics and AI at AstraZeneca, where he has held roles of increasing responsibility for more than a decade. Prior to that he held positions at European Molecular Biology Laboratory’s European Bioinformatics Institute and at Tangram Therapeutics (formerly e-therapeutics).  

Rui Wang, Evotec’s incoming Head of Global In Silico and AI, added, “The companies that will lead in AI-enabled drug discovery are those that learn from the right data, generated against the right biological questions, at scale. Evotec is uniquely positioned at the intersection of discovery, data and proprietary platforms. Our focus is to translate this position into a durable scientific advantage by concentrating on the capabilities where we can truly differentiate – scaling them with depth and rigor.”